Christopher Stevo | SVP & Chief IR Officer |
Albert Bourla | Chairman & CEO |
David Denton | CFO & EVP |
Mikael Dolsten | President, Worldwide Research and Development and Medical |
Aamir Malik | Chief Business Innovation Officer |
Angela Hwang | Chief Commercial Officer and President, Global Biopharmaceuticals Business |
William Pao | EVP & Chief Development Officer |
Colin Bristow | UBS |
Louise Chen | Cantor |
Stephen Scala | Cowen |
Robyn Karnauskas | Truist Securities |
Brian Tsang | Wolfe Research |
Terence Flynn | Morgan Stanley |
Umer Raffat | Evercore ISI |
Geoff Meacham | Bank of America Merrill Lynch |
Christopher Schott | JPMorgan Chase & Co. |
David Risinger | SVB Securities |
Chris Shibutani | Goldman Sachs |
Andrew Baum | Citigroup |
Mohit Bansal | Wells Fargo Securities |
Evan Seigerman | BMO Capital Markets |
Good day, everyone, and welcome to Pfizer's Third Quarter 2022 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Mr. Chris Stevo, Senior Vice President and Chief Investor Relations Officer. Please go ahead, sir.